Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life

Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitti...

Descripción completa

Detalles Bibliográficos
Autores principales: Severi, Stefano, Grassi, Ilaria, Nicolini, Silvia, Sansovini, Maddalena, Bongiovanni, Alberto, Paganelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293504/
https://www.ncbi.nlm.nih.gov/pubmed/28203088
http://dx.doi.org/10.2147/OTT.S97584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293504/
https://www.ncbi.nlm.nih.gov/pubmed/28203088
http://dx.doi.org/10.2147/OTT.S97584

Ejemplares similares